Neutrophils, an abundant cell type at sites of inflammation, have the ability to produce a number of cytokines, including interleukin 1 (IL-1), IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor alpha (TNF-alpha). In this study, we have examined the ability of human neutrophils to produce the IL-1 receptor antagonist (IL-1Ra), a 17-23-kD protein recently isolated and cloned from macrophages. Since IL-1Ra has been shown to inhibit both the in vitro and in vivo effects of IL-1, its production by large numbers of tissue-invading neutrophils might provide a mechanism by which the effects of IL-1 are regulated in inflammation. Using antibodies that are specific for IL-1Ra and a cDNA probe encoding for this protein, we were able to show that neutrophils constitutively produce IL-1Ra. However, after activation by GM-CSF and TNF-alpha, IL-1Ra was secreted into the extracellular milieu where it constituted the major de novo synthesized product of activated neutrophils. None of a large array of other potent neutrophil agonists were found to affect the production of IL-1Ra by neutrophils. Quantitative measurements by enzyme-linked immunosorbent assay revealed that intracellular IL-1Ra is in eightfold excess of the amount secreted in supernatants when studying nonactivated neutrophils. However, in GM-CSF- and TNF-alpha-activated cells, this difference was reduced to values between four- and fivefold, as virtually all of the de novo synthesized IL-1Ra was secreted. In activated cells, the intracellular content of IL-1Ra was found to be in the 2-2.5-ng/ml range per 10(6) neutrophils, whereas levels reached the 0.5-ng/ml range in supernatants. This would imply that IL-1Ra is produced in excess of IL-1 by a factor of at least 100, an observation that is in agreement with the reported amounts of IL-1Ra needed to inhibit the proinflammatory effects of IL-1. Neutrophils isolated from an inflammatory milieu, the synovial fluid of patients with rheumatoid arthritis, were found to respond to GM-CSF and TNF-alpha in terms of IL-1Ra synthesis, indicating that the in vitro observations made in this study are likely to occur in an inflammatory setting in vivo.
Skip Nav Destination
Article navigation
1 August 1992
Article|
August 01 1992
Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha.
S R McColl,
S R McColl
Centre de Recherche en Inflammation, Université Laval, Québec, Canada.
Search for other works by this author on:
R Paquin,
R Paquin
Centre de Recherche en Inflammation, Université Laval, Québec, Canada.
Search for other works by this author on:
C Ménard,
C Ménard
Centre de Recherche en Inflammation, Université Laval, Québec, Canada.
Search for other works by this author on:
A D Beaulieu
A D Beaulieu
Centre de Recherche en Inflammation, Université Laval, Québec, Canada.
Search for other works by this author on:
S R McColl
Centre de Recherche en Inflammation, Université Laval, Québec, Canada.
R Paquin
Centre de Recherche en Inflammation, Université Laval, Québec, Canada.
C Ménard
Centre de Recherche en Inflammation, Université Laval, Québec, Canada.
A D Beaulieu
Centre de Recherche en Inflammation, Université Laval, Québec, Canada.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1992) 176 (2): 593–598.
Citation
S R McColl, R Paquin, C Ménard, A D Beaulieu; Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha.. J Exp Med 1 August 1992; 176 (2): 593–598. doi: https://doi.org/10.1084/jem.176.2.593
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement